Ahpra registration PHY0002298174
How these guides are written and reviewed →
Some autoimmune conditions — the ones that cause joint pain, skin tightening or muscle weakness — can also affect the lungs. The immune system inflames the fine tissue between the air sacs, and over time this can leave scarring that makes the lungs stiffer and less able to move oxygen into the blood. The usual symptoms are breathlessness on exertion and a dry cough, and they often creep up so slowly that they get blamed on being unfit or on the joints. This kind of lung scarring is different from most in one important way: because it is driven by the immune system, treatment that calms the immune system can slow it or improve it. That is why breathlessness in someone with an autoimmune condition is always worth reporting rather than putting up with.
Definition
Connective tissue disease-associated interstitial lung disease is inflammation and scarring of the lung tissue occurring as a manifestation of a systemic autoimmune disease. It sits within the broader family of interstitial lung diseases, and it is distinguished from idiopathic pulmonary fibrosis by having an identifiable systemic cause — which matters, because that cause is often treatable.
Which diseases, and how often
| Underlying disease | Lung involvement | Usual pattern |
|---|---|---|
| Systemic sclerosis (scleroderma) | The most frequent and the most consequential; ILD is a leading cause of death in this disease | NSIP most commonly, lower zones |
| Rheumatoid arthritis | Common; clinically significant in a minority but that minority does poorly | UIP more often than in other CTDs — which is why it behaves worse |
| Idiopathic inflammatory myopathies | Frequent, and can present with the lungs before the muscles | NSIP or organising pneumonia; anti-MDA5 disease can be rapidly progressive |
| Sjögren syndrome | Less common, usually indolent | NSIP, lymphocytic interstitial pneumonia, airway disease |
| Mixed CTD and lupus | Uncommon as significant ILD; lupus more often causes pleural disease | Variable |
A related group has features of autoimmunity that fall short of a defined connective tissue disease — described as interstitial pneumonia with autoimmune features. These patients are managed in the same services and much of the same reasoning applies.
Pathophysiology
Immune injury, then remodelling
The initiating event is immune-mediated injury to the alveolar walls and the small vessels within them. Inflammatory cells accumulate in the interstitium; repeated or sustained injury drives fibroblast activation and collagen deposition. Because the inflammatory phase often precedes and coexists with the fibrotic one, immunosuppression can genuinely alter the course — the opposite of the situation in IPF, where the process is fibrotic from the outset and immunosuppression causes harm.
Why the lung is not the whole problem
Breathlessness in these patients is rarely explained by the lung alone. Skin tightening restricts chest wall movement in scleroderma; myositis weakens the respiratory muscles directly; anaemia, deconditioning, joint pain limiting activity, pulmonary hypertension and cardiac involvement all contribute. Assessment that stops at the CT and the spirometry will misattribute the symptom.1
Co-morbidities
- Pulmonary hypertension — particularly in systemic sclerosis, where it may occur with or without ILD and changes both prognosis and treatment; see pulmonary hypertension.
- Gastro-oesophageal reflux and oesophageal dysmotility — near-universal in scleroderma, and a plausible contributor to lung injury through microaspiration.
- Respiratory muscle weakness — the dominant mechanism in myositis, and one that spirometry alone will not distinguish from parenchymal restriction.
- Joint disease and deformity — limits exercise mode and grip, and shapes what a rehabilitation programme can realistically prescribe.
- Infection risk — a direct consequence of immunosuppression, and the reason new breathlessness is never assumed to be progression.
- Osteoporosis, diabetes and myopathy — from long-term corticosteroid exposure.
- Cardiac involvement — myocardial disease in scleroderma and myositis, pericardial disease in lupus.
Prevalence
CTD-ILD accounts for a substantial share of all interstitial lung disease. The frequency depends heavily on how hard it is looked for: sensitive CT screening finds lung changes in the majority of patients with systemic sclerosis, while clinically significant, progressive disease affects a much smaller proportion. In rheumatoid arthritis the pattern is reversed — subclinical changes are common, overt ILD is uncommon, but when it occurs it carries a worse prognosis than most other CTD-ILDs because of its tendency to a UIP pattern.2
Causes and risk
- The autoimmune disease itself — and, importantly, its antibody profile: anti-Scl-70 (topoisomerase I) in scleroderma, anti-synthetase and anti-MDA5 in myositis, and citrullinated-peptide antibodies in rheumatoid disease all raise ILD risk.
- Male sex and older age at onset — associated with worse lung outcomes in several of these diseases.
- Smoking — a risk factor for rheumatoid arthritis itself and for its lung involvement.
- Diffuse rather than limited cutaneous scleroderma — higher risk and earlier onset.
- Drug-induced lung injury — methotrexate and other agents can cause pneumonitis, which must be distinguished from disease progression.
Symptoms
What patients notice
- Breathlessness on exertion, developing over months, often attributed to deconditioning or to joint limitation.
- A persistent dry cough.
- Fatigue that is disproportionate and hard to separate from the underlying disease.
- Reduced exercise tolerance noticed first on hills, stairs, or carrying.
- Frequently, nothing at all — which is the argument for screening rather than waiting for symptoms.
Warning signs
Diagnosis
Screening, not just diagnosis
Because symptoms lag behind disease, screening is now recommended at diagnosis in high-risk connective tissue diseases — particularly systemic sclerosis — with high-resolution CT and lung function rather than symptoms alone. Finding disease before it is symptomatic is what makes early treatment possible.
How it is assessed
- High-resolution CT — defines the pattern (NSIP, UIP, organising pneumonia) and the extent, which together carry most of the prognostic information.
- Lung function — FVC and gas transfer (DLCO), interpreted as a trajectory across serial tests rather than a single value. A falling DLCO out of proportion to FVC raises the question of pulmonary hypertension.
- Autoantibody profile — identifies the underlying disease and stratifies risk.
- Six-minute walk test with oximetry — exertional desaturation and walk distance track function better than resting numbers.
- Echocardiography — screening for pulmonary hypertension and cardiac involvement.
- Bronchoscopy or biopsy — used selectively, mainly to exclude infection or drug reaction rather than to make the diagnosis.
The diagnosis is made in a multidisciplinary discussion between respiratory and rheumatology services, and the distinction from IPF, hypersensitivity pneumonitis and drug toxicity is the main work of that meeting.3
Management
Immunosuppression
This is the point of difference from most fibrotic lung disease. Mycophenolate and cyclophosphamide have both been shown to preserve lung function in scleroderma-associated ILD, with mycophenolate now generally preferred on tolerability. Rituximab and tocilizumab have roles in selected patients. Corticosteroids are used cautiously in scleroderma because of the risk of renal crisis at higher doses. Treatment is prescribed and monitored by rheumatology and respiratory specialists together.
Antifibrotic therapy
Nintedanib slows lung function decline in scleroderma-associated ILD and in progressive fibrosing ILD of other causes, and can be used alongside immunosuppression. It treats the fibrotic process rather than the autoimmune one, so it complements rather than replaces immunosuppression.
Treating everything else
Living with CTD-ILD
Two diseases, one person
Patients frequently attend separate rheumatology and respiratory clinics, receive advice from both, and are left to reconcile it. Asking who is coordinating care, and whether the two teams communicate, is a reasonable and useful question for a patient to raise.
Energy, pacing and flares
Fatigue here is the sum of autoimmune disease activity, breathlessness, poor sleep, medication and deconditioning. Pacing strategies that work for joint flares generally transfer well to breathlessness, and patients often already have them.
Exercise with joints and skin involved
Exercise is beneficial and safe, but the mode has to fit: water-based work where joints are painful, seated or supported options where balance or skin tightness limits, upper-limb work adapted around hand involvement. The principle is that the programme adapts to the person, not the reverse.
Monitoring
Regular lung function is how progression is detected before it is felt. Encourage patients to attend it even when they feel stable — the numbers move first.
Prognosis
Outcome varies widely by underlying disease, CT pattern, extent at diagnosis and rate of change. Extensive disease and a UIP pattern — more common in rheumatoid arthritis — carry the worst outlook, while limited NSIP that stabilises on treatment may not shorten life. Serial lung function is the most useful prognostic tool available, and the trajectory over six to twelve months tells more than any single measurement.4
Role of the physiotherapist
Assessment
Assess breathlessness against a validated scale, exercise capacity and desaturation on a walk test, respiratory muscle strength where myositis is in play, chest wall excursion where skin involvement restricts it, and the musculoskeletal factors that will shape the programme — hand function, joint range, pain and balance. Establish which limitation actually stops the patient: it is often not the lung.
Exercise training
Aerobic and resistance training both improve capacity. Use interval formats where desaturation or fatigue limits continuous work, oxygen during training where it permits a higher work rate, and modes that accommodate joints. Progress on symptoms. Steroid myopathy and disuse atrophy both respond to resistance work, and it is frequently the omitted component.
Breathlessness and chest wall work
Positioning, the handheld fan, breathing control and pacing address the symptom directly. In scleroderma with restrictive skin involvement, thoracic mobility and stretching have a plausible role, though the evidence is thin. See managing breathlessness.
Coordination and safety
Know the patient’s immunosuppression and what it means for infection risk and for exercising alongside others. Report a step-change in breathlessness, new desaturation or a fall in exercise tolerance to the treating team rather than adjusting the programme around it — in this population, deterioration is a clinical event, not a training problem.
Part 1 · References
- Wells AU, Denton CP. Interstitial lung disease in connective tissue disease — mechanisms and management. Nat Rev Rheumatol 2014;10(12):728–739.
- Jeganathan N, Sathananthan M. Connective tissue disease-related interstitial lung disease: prevalence, patterns, predictors, prognosis, and treatment. Lung 2020;198(5):735–759.
- Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2022;205(9):e18–e47.
- Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008;177(11):1248–1254.
References are numbered in citation order (Vancouver/BMJ style) and were current at the time of writing. Guidelines are living documents — verify against the latest version before clinical use.
Supervised exercise, breathing technique and self-management education are the mainstay of cardiorespiratory physiotherapy for this condition.
Clinical evidence
Part 1 covers the same condition without the technical detail. What follows is the evidence base behind it, written for clinicians — the literature, the reasoning and the gaps.
For clinicians: this summary supports clinical reasoning and is not a protocol. Check current guidelines and local policy before applying it, and read it alongside the key references and guidelines directory.
Framing. CTD-ILD is the counterexample to the fibrosis literature. Where immunosuppression is harmful in IPF, two randomised trials in scleroderma-associated disease showed it preserves lung function; and where antifibrotics were once IPF-specific, SENSCIS and INBUILD extended them into this population. The current questions are therefore not whether to treat but which mechanism to target, in which order, and whether to target both at once — and the trials were not designed to answer that.1,2,3
Treatment evidence
- Scleroderma Lung Study I randomised oral cyclophosphamide against placebo in symptomatic scleroderma-ILD and showed a modest but significant preservation of FVC at 12 months. The effect dissipated within a year of stopping, establishing both that the disease is treatable and that the treatment does not cure it.1
- Scleroderma Lung Study II compared mycophenolate for two years against cyclophosphamide for one. Both improved FVC with no significant difference between them, and mycophenolate was better tolerated with less toxicity — which is why it became first-line despite not having beaten the comparator.2
- SENSCIS randomised nintedanib in scleroderma-ILD and showed a reduced rate of FVC decline. Around half the cohort was on background mycophenolate, and the effect was directionally consistent in that subgroup — the main basis for combining an antifibrotic with immunosuppression, though the trial was not powered for the interaction.3
- INBUILD extended nintedanib to progressive fibrosing ILD irrespective of cause, including a substantial autoimmune subgroup, with a consistent effect on FVC decline across diagnoses. This reframed treatment around behaviour — progression — rather than around diagnostic label.4
- Tocilizumab (focuSSced) did not meet its primary skin endpoint but showed preservation of FVC in early diffuse scleroderma with inflammatory markers, and is now approved for scleroderma-ILD in some jurisdictions on that secondary signal.5
- Rituximab in the RECITAL trial was non-inferior to cyclophosphamide across CTD-ILD, with fewer adverse events — a useful option rather than a demonstrated advance.6
- Pulmonary rehabilitation improves exercise capacity and quality of life in fibrotic ILD; the Cochrane review reports gains in walk distance and dyspnoea that attenuate over six to twelve months without maintenance. CTD-specific trials are small, and none has adapted the intervention systematically to musculoskeletal limitation.7
Clinical reasoning
- Screen rather than wait for symptoms. In systemic sclerosis, HRCT plus lung function at diagnosis detects disease well before breathlessness, and extent at detection is prognostic. Symptom-triggered investigation systematically finds it late.
- Extent and trajectory carry the prognosis. The Goh staging system — CT extent above or below 20%, with FVC used where extent is indeterminate — remains the practical stratifier, and serial change over 6–12 months informs more than any baseline value.8
- Rheumatoid ILD behaves differently. Its greater tendency to a UIP pattern brings a worse prognosis and imports the IPF caution about immunosuppression. Treatment decisions here are less well evidenced than in scleroderma and should not be extrapolated from it.
- New breathlessness in an immunosuppressed patient is a differential, not a trajectory. Infection, drug-induced pneumonitis, pulmonary hypertension, cardiac involvement and progression all present identically and are managed in opposite directions.
- A DLCO falling out of proportion to FVC should prompt evaluation for pulmonary hypertension, particularly in scleroderma, where it may be present without significant parenchymal disease.
- Avoid high-dose corticosteroids in scleroderma — the association with renal crisis is the reason immunosuppressive strategy here differs from other CTD-ILDs.
- Spirometric restriction is not necessarily parenchymal. In myositis, respiratory muscle weakness produces the same FVC pattern; maximal inspiratory and expiratory pressures separate them, and the treatment implication is entirely different.
- Rehabilitation prescription must start from the musculoskeletal assessment. Joint pain, hand involvement, skin restriction and myopathy determine the achievable mode; a standard COPD-derived circuit will fail in this population for reasons unrelated to the lung.
Evidence gaps
- No trial has directly tested combination immunosuppression plus antifibrotic against either alone; the practice rests on a SENSCIS subgroup.
- Whom to treat and when to start remain unresolved — particularly in screen-detected, asymptomatic, limited disease, where the trials enrolled symptomatic patients.
- Rheumatoid ILD is under-represented in randomised evidence despite carrying the worst prognosis of the common CTD-ILDs.
- Optimal duration of therapy, and whether it can ever be withdrawn, are unknown; SLS I showed loss of benefit after cessation but no strategy trial has followed it.
- Rehabilitation evidence comes from mixed-ILD cohorts. Adaptation for joint, skin and muscle involvement, oxygen use during training, and maintenance beyond the supervised programme are all untested.
- No validated composite outcome exists that captures lung, skin, joint and muscle disease together, so trials optimise one organ at a time in a multi-organ disease.
References for the clinical evidence summary
- Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354(25):2655–2666.
- Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II). Lancet Respir Med 2016;4(9):708–719.
- Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease (SENSCIS). N Engl J Med 2019;380(26):2518–2528.
- Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases (INBUILD). N Engl J Med 2019;381(18):1718–1727.
- Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis (focuSSced): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2020;8(10):963–974.
- Maher TM, Tudor VA, Saunders P, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease (RECITAL). Lancet Respir Med 2023;11(1):45–54.
- Dowman L, Hill CJ, May A, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev 2021;(2):CD006322.
- Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008;177(11):1248–1254.
Corrections: If something on this page is wrong, out of date or unclear, we want to know. Email reception@inspireclinic.au with the page name and what you believe is incorrect. Substantive corrections are made promptly, and the guide’s version and last-updated date are changed to reflect it.